EUROPEAN VISION INSTITUTE - EEIG

Their core work

The European Vision Institute is a European Economic Interest Grouping — a cross-border legal entity that networks ophthalmology research institutions across Europe. Rather than conducting independent lab work, it functions as a coordinating infrastructure for vision science, connecting member institutes and providing an organizational home for multi-country training initiatives in eye disease research. In H2020, it appeared in two Marie Skłodowska-Curie Innovative Training Networks as a third-party contributor, meaning it hosted or supported early-career researchers within its member network without carrying direct EC funding. Its core value is as a pan-European gateway into the ophthalmology research community, particularly for inherited and degenerative retinal diseases.

What they specialise in

How they've shifted over time

Both H2020 projects launched within a year of each other (2017 and 2018), so a temporal evolution is difficult to establish with confidence. However, the keyword profile reveals a meaningful thematic shift: the earlier transMed project left no specific technical keywords, suggesting a broad translational medicine mandate, while StarT generated a precise cluster — genomics, genome editing, stem cell biology, photoreceptor cells, Stargardt disease — pointing toward molecular and genetic approaches to a specific inherited condition. The overall trajectory moves from broad disease-area training toward targeted gene-therapy-adjacent research methodologies.

EVI appears to be gravitating from broad ophthalmology training toward molecular genetics and therapy development for specific inherited retinal conditions — a niche directly relevant to gene therapy and precision medicine consortia.

How they like to work

EVI has participated exclusively as a third party in both recorded H2020 projects, meaning it contributes capacity, hosting, or network access without leading consortia or holding primary participant status. Despite this modest formal role, it maintains a notable network footprint — 27 unique partners across 11 countries from only two projects — suggesting its EEIG structure actively draws in a wide membership base. Working with EVI likely means accessing its member institutes rather than the institute itself as a direct research executor.

With 27 unique consortium partners across 11 countries from just two projects, EVI demonstrates a broad European reach disproportionate to its project count. Its EEIG legal form is designed precisely for cross-border networking, making this wide partner spread a structural feature rather than coincidence.

What sets them apart

As a European Economic Interest Grouping rather than a traditional research institute, EVI occupies a rare structural niche: it is built explicitly to bridge national ophthalmology research communities across the EU without competing with them. Any consortium seeking credible pan-European access to vision science labs, patient cohorts, or clinical ophthalmology infrastructure would find EVI a uniquely well-positioned entry point. Its specific depth in inherited retinal disease — particularly Stargardt and related photoreceptor degenerations — is narrow enough to be genuinely differentiated.

Highlights from their portfolio

• StarT
  A focused European Training Network targeting Stargardt Disease specifically — combining genomics, genome editing, and stem cell biology — representing EVI's deepest documented technical engagement and the most precise disease-area commitment in its H2020 record.
• transMed
  EVI's earliest H2020 appearance, in a translational medicine training network for eye diseases, establishing its role as an MSCA host infrastructure and signaling its institutional mandate to develop the next generation of vision scientists.